OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 29, 2020
NanoMab Technology has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta.
October 15, 2020
Recent data, from BIA and Clarivate, has revealed that investment in UK biotech continues to be strong.
October 01, 2020
Optimus Holding has successfully completed the acquisition of OM Pharma.
August 13, 2020
Stringent patentability requirements present a challenge to obtaining broad-based antibody claims, so companies should develop a strategy based on multiple reinforcing layers of protection.
July 21, 2020
Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.
July 20, 2020
A strong immune response by patients receiving two doses of AZD1222 vaccine suggests a possible dosing strategy for COVID-19 vaccine.
July 08, 2020
VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.
June 30, 2020
The company now offers its CONFIDENCE virus clearance services to support validation of viral clearance processes.
June 15, 2020
Citing clinical trial data that hydroxychloroquine did not show benefits for COVID-19 patients, FDA removes emergency use authorization for the drug as a treatment for the novel coronavirus.
June 08, 2020
Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate.
June 01, 2020
The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.
The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.
Achieving herd immunity will require testing, data, a vaccine, and public support.
Working with incubators can provide cell and gene therapy developers with more opportunities.
May 20, 2020
This latest round of funding adds 14 new technology projects, workforce development, and Global Health Fund projects to NIIMBL's portfolio.
May 19, 2020
Participants in two dosing cohorts in Moderna’s mRNA-1273 study reached or exceeded neutralizing antibody titers generally seen in convalescent sera.
May 05, 2020
Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.
FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.
May 02, 2020
FDA’s EUA provides the first new treatment for COVID-19 patients with severe symptoms.
May 01, 2020
Will moving at “warp speed” to develop a vaccine impact efficacy or safety?